Publications

Zocchi L, Benavente CA. (2018) DNA repair and epigenetic regulation in cancer. Molecular Medicines for Cancer: Concepts and Applications of Nanotechnology, CRC Press/Taylor & Francis Publishers, in press.

Zocchi L, Wu SC,  Wu J, Hayama KL, Benavente CA. (2018) The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget,  9(34):23505-23518.

Aldiri I, Ajioka I, Beisi X, Zhang J, Chen X, Benavente C, Finkelstein D, Johnson D, Akiyama J, Pennacchio L, Dyer MA. (2015) Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma. Development, 142(23):4092-106.

Benavente CA, Dyer MA. (2015). Genetically engineered mouse and orthotopic human tumor xenograft models of retinoblastoma. In Methods in Molecular Biology. (pp. 307-17). New York: Springer Science+Business Media.

Benavente CA, Dyer MA. (2015). Genetics and Epigenetics of Human Retinoblastoma. Annual Reviews of Pathology: Mechanisms of Disease,(10), 547-562.

Steward E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA. (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Reports, 9(3):829-41.

Benavente CA, Finkelstein D, Johnson DA, Marine JC, Ashery-Padan R, Dyer MA. (2014). Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression. Oncotarget, 5(20), 9594-608.

Benavente CA, McEvoy JD, Finkelstein D, Wei, L., Kang, G., Wang, Y. D., Neale, G., Ragsdale, S., Valentine, V., Bahrami, A., Temirov, J., Pounds, S., Zhang, J., Dyer, M. A. (2013). Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget, 4(6), 844-59.

Zhang J*, Benavente CA*, McEvoy J*, Flores-Otero J*, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER, Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA. (2012). A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature, 481(7381), 329-34. 0028-0836. *Authors contributed equally to this manuscript. Faculty of 1000 (F1000)

Benavente CA, Schnell SA, Jacobson EL. (2012). Effects of niacin restriction on sirtuin and PARP responses to photodamage in human skin. PloS ONE, 7(7), e42276.

Bermudez Y, Benavente CA, Meyer RG, Coyle WR, Jacobson MK, Jacobson EL. (2011). Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation. PloS ONE, 6(5), e20487.

Benavente CA, Jacobson MK, Jacobson EL. (2009). NAD in skin: therapeutic approaches for niacin. Current pharmaceutical design, 15(1), 29-38. 1381-6128.

Benavente CA, Jacobson EL. (2008). Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes. Free radical biology & medicine, 44(4), 527-37. 0891-5849.

Benavente CA., Sierralta WD, Conget PA, Minguell JJ. (2003). Subcellular distribution and mitogenic effect of basic fibroblast growth factor in mesenchymal uncommitted stem cells. Growth factors, 21(2), 87-94. 0897-7194.